Clinical - Phase News: Breaking Clinical - Phase News, Comments and Articles. - Page: 5

Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy

MIAMI , May 17, 2013 /- Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound IN...

Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

Researchers at Cedars-Sinai have launched a new clinical trial to investigate the effects of a cancer-fighting drug therapy that has shown favorable outcomes in patients with advanced metastatic prostate cancer.

Alcoholics Who Smoke May Face Early Brain Aging

FRIDAY, May 17 (HealthDay News) -- Alcoholics who smoke have more problems with memory, problem solving and quick thinking than those who are nonsmokers, researchers have found. This "early aging" of the brain gets worse over time, according to the...

Statistical Challenges in Medical Device Trail Evaluation

SHANGHAI , May 17, 2013 /- Medical devices are any medical items that are neither a drug nor a biological product. In light of their different mechanisms, actions and regulatory requirements, medical device (MD) trail evaluations are much more compl...

A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing

SINGAPORE and ZURICH, May 17, 2013 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase...

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

NORTH CHICAGO, Ill. and MECHELEN, Belgium, May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease.  Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.  Upon successful c...

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital...

[Comment] Post-mortem diagnosis: evolving a team approach

The decline in autopsy rates in the past four decades in developed countries (to less than 5% in the USA) has paralleled continued discrepancies between clinical and autopsy diagnoses of up to 20–30%. However, uncertainty about the accuracy of less...

Novel Two-step Immunotherapy Shows Promise in Recurrent Ovarian Cancer

A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, according to data from two phase I clinical trials presented at the American Association for Cancer Research (AACR) Annual Meeti...

Relationship Between Sleep Duration And Suicidal Thoughts In People With Insomnia.

Results of a new study show that every one-hour increase in sleep duration was associated with a 72 percent decrease in the likelihood of moderate or high suicide risk, in comparison with low risk. Data were adjusted for age, gender, race/ethnicity,...

Data Addressing Patient And Physician Barriers To Clinical Trials To Be Presented By Experts

Researchers from University Hospitals Case Medical Center's (UHCMC) Seidman Cancer Center in Cleveland, OH, will present findings from two studies evaluating new technologies designed to address common barriers to patient enrollment in clinical trial...

Experts Challenge Assumption, Describe Pathway That Leads To Organ Rejection

Transplant researchers at the University of Pittsburgh School of Medicine challenge a long-held assumption about how biologic pathways trigger immune system rejection of donor organs in a report published online today in the Journal of Clinical Inves...

Depressed Patients Have As Many Goals As Healthy People, But Describe Them In Vague Terms

People suffering from clinical depression express personal goals and reasons for their attainment or failure in less specific terms than people without the disorder. This lack of specificity in representing personal goals may be partially responsible...

Signals Identified That Direct The Immune System To Reject A Transplanted Organ

Organ transplant rejection occurs when the transplant recipient's immune system identifies the transplanted organ as foreign tissue and attacks it. It was previously thought that T cells, the immune cells that mediate rejection, must first be activat...

Cytomedix to Present at the World Stem Cells & Regenerative Medicine Congress 2013

GAITHERSBURG, MD -- (Marketwired) -- 05/17/13 -- Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Edward Field, the Company's Chief Operating Officer, has been invited to make a presentation on Partnering & Collaboration at the World Stem Cells & Regenerative Medicine C...

Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B

BAGSVAERD, DENMARK -- (Marketwired) -- 05/17/13 -- Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm™ 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients wi...

AREVA Med Presents Pharmacokinetics Data From Phase 1 Clinical Trial at SNMMI

BETHESDA, Md., May 17, 2013 (GLOBE NEWSWIRE) -- AREVA Med, an AREVA subsidiary specializing in the development of new innovative therapies to fight cancer, announced today that it will present pharmacokinetics data on the company's ongoing Phase 1 clinical trial of its alpha radioimmunotherapy 212Pb-TCMC-Trastuzumab in patients with intra-abdominal cancers. The data will be presented at the Soci...

Med BioGene Inc. Comments on Market Activity

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/17/13 -- Med BioGene Inc. (TSX VENTURE: MBI) today, at the request of the Investment Industry Regulatory Organization of Canada (IIROC), announced that Med BioGene's management is unaware of any material change in the company's operations that would account for the recent increase in market activity. About Med BioGene Inc. Med BioGene is a lif...

The Pupillometer in Nursing Practice

An ICU neuroscience clinical nurse specialist answers key questions about this invaluable assessment tool.

Most cancer patients would like to talk with their doctors about financial concerns

Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report. Yet many patients...

Quintiles Signs Exclusive Development Deal with Merck Days After $1B IPO

Just days after raising more than $1B in its IPO, Quintiles announced Wednesday it signed a five-year clinical development agreement with Merck Serono. 

Blocking The Protein-Protein Interaction Which Causes Ewing Sarcoma

Continuous infusion of a novel agent not only halted the progression of Ewing sarcoma in rats, while some tumors also regressed to the point that cancer cells could not be detected microscopically, say researchers at Georgetown Lombardi Comprehensive...

Molecular Profiling Timely For Tailoring Cancer Therapy

A clinical trial has shown that patients, and their physicians, are eager to jump into next-era cancer care - analysis of an individual's tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, are being presen...

Combination Drug Therapy May Be Best Treatment For Osteoporosis

The combination of two different drugs for osteoporosis was found to increase bone mineral density (BMD) more than treatment with either drug alone, according to the results of a small clinical trial published in The Lancet. The combination, which in...

Surveillance Best Follow-Up Strategy Among Men With Stage I Seminoma

A long-term study of men with stage I seminoma, a common form of testicular cancer, suggests that surveillance for cancer recurrence, rather than additional chemotherapy or radiation therapy, is sufficient for the vast majority of patients who have u...